X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA IPCA LABS PLETHICO PHARMA/
IPCA LABS
 
P/E (TTM) x -1.1 38.9 - View Chart
P/BV x 0.0 3.0 0.6% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PLETHICO PHARMA   IPCA LABS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
IPCA LABS
Mar-17
PLETHICO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs395643 61.4%   
Low Rs31503 6.2%   
Sales per share (Unadj.) Rs604.4254.4 237.6%  
Earnings per share (Unadj.) Rs32.516.1 202.1%  
Cash flow per share (Unadj.) Rs51.329.8 172.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs473.6194.6 243.4%  
Shares outstanding (eoy) m34.08126.20 27.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.3 15.7%   
Avg P/E ratio x6.635.7 18.4%  
P/CF ratio (eoy) x4.219.2 21.6%  
Price / Book Value ratio x0.52.9 15.3%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m7,26272,300 10.0%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,5966,960 22.9%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m20,59832,106 64.2%  
Other income Rs m386226 171.2%   
Total revenues Rs m20,98432,332 64.9%   
Gross profit Rs m2,8184,448 63.3%  
Depreciation Rs m6421,730 37.1%   
Interest Rs m1,593241 661.6%   
Profit before tax Rs m9692,703 35.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138675 -20.5%   
Profit after tax Rs m1,1072,028 54.6%  
Gross profit margin %13.713.9 98.7%  
Effective tax rate %-14.325.0 -57.2%   
Net profit margin %5.46.3 85.1%  
BALANCE SHEET DATA
Current assets Rs m18,87717,340 108.9%   
Current liabilities Rs m11,8969,559 124.4%   
Net working cap to sales %33.924.2 139.8%  
Current ratio x1.61.8 87.5%  
Inventory Days Days36100 35.8%  
Debtors Days Days19857 347.9%  
Net fixed assets Rs m9,86120,779 47.5%   
Share capital Rs m341252 135.0%   
"Free" reserves Rs m12,33124,499 50.3%   
Net worth Rs m16,13924,553 65.7%   
Long term debt Rs m4,7063,517 133.8%   
Total assets Rs m33,14639,595 83.7%  
Interest coverage x1.612.2 13.2%   
Debt to equity ratio x0.30.1 203.5%  
Sales to assets ratio x0.60.8 76.6%   
Return on assets %8.15.7 142.2%  
Return on equity %6.98.3 83.0%  
Return on capital %12.310.5 117.2%  
Exports to sales %21.448.6 43.9%   
Imports to sales %15.214.2 106.9%   
Exports (fob) Rs m4,40215,617 28.2%   
Imports (cif) Rs m3,1364,571 68.6%   
Fx inflow Rs m4,40215,617 28.2%   
Fx outflow Rs m3,1845,828 54.6%   
Net fx Rs m1,2199,790 12.4%   
CASH FLOW
From Operations Rs m2,4372,764 88.2%  
From Investments Rs m-6,265-1,432 437.6%  
From Financial Activity Rs m2,490-1,591 -156.5%  
Net Cashflow Rs m-1,337-259 516.7%  

Share Holding

Indian Promoters % 82.7 45.9 180.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.4 37.7%  
FIIs % 5.5 25.3 21.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.4 43.1%  
Shareholders   10,665 36,892 28.9%  
Pledged promoter(s) holding % 85.7 2.1 4,006.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Power Stocks Top Losers(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS